Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Medtronic
Boehringer Ingelheim
Argus Health
Mallinckrodt
Queensland Health
Express Scripts
Daiichi Sankyo
Accenture

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011145

« Back to Dashboard

NDA 011145 describes DIURIL, which is a drug marketed by Oak Pharms Akorn and Salix Pharms and is included in two NDAs. It is available from three suppliers. Additional details are available on the DIURIL profile page.

The generic ingredient in DIURIL is chlorothiazide. There are forty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the chlorothiazide profile page.
Summary for 011145
Tradename:DIURIL
Applicant:Oak Pharms Akorn
Ingredient:chlorothiazide
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 011145
Ingredient-typeThiazides
Physiological EffectIncreased Diuresis
Medical Subject Heading (MeSH) Categories for 011145
Suppliers and Packaging for NDA: 011145
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIURIL chlorothiazide sodium INJECTABLE;INJECTION 011145 NDA AUTHORIZED GENERIC Akorn, Inc. 17478-419 N 17478-419-40
DIURIL chlorothiazide sodium INJECTABLE;INJECTION 011145 NDA Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.) 76478-711 N 76478-711-40

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Profile for product number 005

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
McKesson
Cantor Fitzgerald
Argus Health
AstraZeneca
Johnson and Johnson
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.